How to buy Avenue Therapeutics stock | $1.33

Avenue Therapeutics Inc is a biotechnology business based in the US. Avenue Therapeutics shares (ATXI) are listed on the NASDAQ and all prices are listed in US Dollars. Avenue Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

Avenue Therapeutics stock price (NASDAQ: ATXI)

Use our graph to track the performance of ATXI stocks over time.

Avenue Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$1.33
52-week range	$1.27 - $7.69
50-day moving average	$1.55
200-day moving average	$2.98
Wall St. target price	$12.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.24

Buy Avenue Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Avenue Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avenue Therapeutics price performance over time

Historical closes compared with the close of $1.33 from 2021-10-21

1 week (2021-10-13)	2.31%
1 month (2021-09-22)	-13.07%
3 months (2021-07-22)	-36.36%
6 months (2021-04-22)	-71.34%

1 year (2020-10-22)	-61.67%
2 years (2019-10-22)	-75.60%
3 years (2018-10-22)	3.41
5 years (2016-10-18)	N/A

Avenue Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-76.43%
Return on equity TTM	-167.32%
Profit margin	0%
Book value	$0.04
Market capitalisation	$21.3 million

TTM: trailing 12 months

Shorting Avenue Therapeutics shares

There are currently 250,169 Avenue Therapeutics shares held short by investors – that's known as Avenue Therapeutics's "short interest". This figure is 10.2% down from 278,439 last month.

There are a few different ways that this level of interest in shorting Avenue Therapeutics shares can be evaluated.

Avenue Therapeutics's "short interest ratio" (SIR)

Avenue Therapeutics's "short interest ratio" (SIR) is the quantity of Avenue Therapeutics shares currently shorted divided by the average quantity of Avenue Therapeutics shares traded daily (recently around 61617.980295567). Avenue Therapeutics's SIR currently stands at 4.06. In other words for every 100,000 Avenue Therapeutics shares traded daily on the market, roughly 4060 shares are currently held short.

However Avenue Therapeutics's short interest can also be evaluated against the total number of Avenue Therapeutics shares, or, against the total number of tradable Avenue Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avenue Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Avenue Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0379% of the tradable shares (for every 100,000 tradable Avenue Therapeutics shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avenue Therapeutics.

Find out more about how you can short Avenue Therapeutics stock.

Avenue Therapeutics share dividends

We're not expecting Avenue Therapeutics to pay a dividend over the next 12 months.

Avenue Therapeutics share price volatility

Over the last 12 months, Avenue Therapeutics's shares have ranged in value from as little as $1.27 up to $7.69. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avenue Therapeutics's is 0.6788. This would suggest that Avenue Therapeutics's shares are less volatile than average (for this exchange).

Avenue Therapeutics overview

Avenue Therapeutics, Inc. , a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York. .

Frequently asked questions

What percentage of Avenue Therapeutics is owned by insiders or institutions?
Currently 60.399% of Avenue Therapeutics shares are held by insiders and 6.867% by institutions. How many people work for Avenue Therapeutics?
Latest data suggests 4 work at Avenue Therapeutics. When does the fiscal year end for Avenue Therapeutics?
Avenue Therapeutics's fiscal year ends in December. Where is Avenue Therapeutics based?
Avenue Therapeutics's address is: 1140 Avenue of the America, New York, NY, United States, 10036 What is Avenue Therapeutics's ISIN number?
Avenue Therapeutics's international securities identification number is: US05360L2051 What is Avenue Therapeutics's CUSIP number?
Avenue Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05360L106